Protherics Plc - Report of Foreign Issuer (6-K)
September 04 2008 - 12:34PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.
20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
02 September 2008
PROTHERICS PLC
(Translation of Registrant’s Name Into
English)
The Heath Business & Technical Park
Runcorn, Cheshire, W47 4QF England
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files
or will file annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
X
Form
40-F
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 191(b)(7):
Indicate by check mark whether the registrant by
furnishing the information contained in this form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act
of 1934.
Yes
No
X
If “Yes” is marked, indicate below the
file number assigned to the registrant in connection with Rule 12g3-2(b):
82-
.
The Registrant is furnishing a copy of its
announcements as reported to the Company Announcements Office of the London Stock
Exchange.
Protherics PLC
Total Voting Rights and Share
Capital
London, UK; Brentwood, TN; 2 September 2008 -
In
conformity with the Transparency Directive, Protherics PLC ("Protherics"), the
international biopharmaceutical company focused on critical care and cancer, notifies
the market of the following:
Protherics' issued share capital consists of
342,203,934 ordinary shares with a nominal value of 2 pence each, with
voting rights. Protherics does not hold any ordinary shares in
Treasury. Therefore, the total number of voting rights
in Protherics is 342,203,934.
The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their interest in,
or a change to their interest in, Protherics under the Financial
Services Authority's Disclosure and Transparency Rules.
| Ends |
For further information please contact:
Protherics
|
|
Nick Staples, Director of Corporate Affairs
|
+44 (0) 7919 480510
|
Julie Vickers, Company
Secretary
|
+44 (0)1928 518010
|
|
|
Financial Dynamics
- press enquiries
|
|
London: Ben Atwell, Lara Mott
|
+44 (0) 20 7831 3113
|
New York: John Capodanno
|
+1 212 850 5600
|
Or visit
www.protherics.com
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
PROTHERICS PLC
|
|
|
|
|
|
|
|
Date: 02 September 2008
|
|
By:
|
|
/s/ Rolf Soderstrom
|
|
|
|
|
Rolf Soderstrom
|
|
|
|
|
Finance Director
|
Protherics (NASDAQ:PTIL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Protherics (NASDAQ:PTIL)
Historical Stock Chart
From Oct 2023 to Oct 2024